
CRXTQ
US listing · $72,828 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 17, 2022 | Time not confirmed | -0.17 | 0.00 | +100.0% |
| Aug 18, 2022 | After the close | -0.29 | -0.24 | +17.2% |
| May 16, 2022 | After the close | -0.40 | -0.61 | -52.5% |
| Mar 30, 2022 | After the close | -0.68 | -0.19 | +72.1% |
| Nov 18, 2021 | After the close | -0.81 | -0.26 | +67.9% |
| Jul 23, 2021 | After the close | -6.26 | -1.98 | +68.4% |
| May 6, 2021 | Time not confirmed | — | -0.65 | — |
| Sep 3, 2020 | Time not confirmed | — | 0.00 | — |
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and…